Keywords: Novartis, Afinitor, pancreatic tumors, NET, Tasigna, Glivec, Gleevec

Novartis’ Afinitor meets primary endpoint in Ph III study of patients with advanced NET; Tasigna shows benefits over Glivec/Gleevec

Article | 04 June 2010

Print This

Novartis announced today that a Phase III study of Afinitor (everolimus) tablets plus best supportive care met its primary endpoint, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in